Nicotinamide Riboside With and Without Resveratrol to Improve Function in Peripheral Artery Disease

Sponsor: Northwestern University
Collaborator: American Heart Association

Purpose

Examine the effects of NR both with and without resveratrol to test whether, among people with PAD, NR with or without resveratrol significantly improves walking performance more than placebo. If hypothesis is supported, large, definitive randomized clinical trial will be designed.

Study Design

Randomized, double-blind, parallel assignment, placebo controlled

Dose

1000mg/day of NR with or without 125mg/day resveratrol, or placebo

Length of Intervention

6 months

Intrinsic Capacity

Locomotion

Status

Recruiting

Condition or Disease 

Peripheral Artery Disease

Timeline estimations sourced on clinicaltrials.gov. All timing subject to change.

Clinical, Heart HealthANAD StaffHeart Health